It Takes a Village: Understanding and Treating Serious Mental Illness

All sessions will be held in Pacific Time (PT).



Saturday, October 14, 2023

7:00 am - 8:00 am

SMI Among Us: Treating Serious Mental Illness in the Community

Stephen M. Stahl, MD, PhD, DSc (Hon.)

Individuals with serious mental illness (SMI), particularly schizophrenia, often need outpatient and community mental health care due to the severity of their illness. Our understanding of the underlying neurobiology of schizophrenia has unfolded to reveal an appreciation that schizophrenia is a brain disease requiring pharmacological intervention. Join Dr. Stephen Stahl as he reviews the neurobiology of SMI, particularly schizophrenia, and the use of pharmacological treatment options in community mental health settings.

8:00 am - 9:00 am

Industry Symposium†: Beyond the Monoamine Hypothesis: A Glutamatergic Approach to Treating Major Depressive Disorder

Presented by Gus Alva, MD, DFAPA

Sponsored by Axsome Therapeutics, Inc.

9:00 am – 9:05 am

Break

9:05 am – 9:35 am

Poster Session†: Safety and Efficacy of KarXT in Schizophrenia in the Randomized, Double-Blind, Placebo-Controlled, Phase 3 EMERGENT-3 Trial

Presented by Scott Vuocolo, PhD

Sponsored by Karuna Therapeutics

9:35 am - 10:35 am

The Long Haul: Long-Term Use of Antipsychotic Treatment in Schizophrenia

Christoph U. Correll, MD

Many patients with schizophrenia require long-term antipsychotic treatment; however, there is some debate about the benefit-risk ratio of such a treatment approach. In this presentation, Dr. Christoph Correll will review the data evaluating outcomes of long-term antipsychotic treatment, as well as the efficacy and safety of various schizophrenia treatments, particularly in the context of long-term treatment.

10:35 am - 11:00 am

Live Panel Q&A

Christoph U. Correll, MD and Stephen M. Stahl, MD, PhD, DSc (Hon.)



†The content of all non-CME/CE events (Industry Symposia, Disease State Sessions, and Poster Sessions) and the views expressed therein are those of the presenting entity and not of NEI. These events are not part of the scientific program and do not provide CME/CE credit. By opening a non-CME/CE event, the attendee opts in to receive follow-up information from the commercial sponsor.



Program Faculty

Christoph U. Correll, MD


Professor of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, New York, NY

Professor of Child and Adolescent Psychiatry, Charité University Medicine, Berlin, Germany


Christoph U. Correll, MD, is Professor of Psychiatry at The Zucker School of Medicine at Hofstra/Northwell, New York, USA, and Professor and Chair of the Department of Child and Adolescent Psychiatry, Charité University Medicine, Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City. Since 1997, he has been working and conducting research in New York, USA, and since 2017 he is also working in Germany.

Dr. Correll focuses on the identification and treatment of youth and adults with severe mental illness, clinical trials, epidemiology, psychopharmacology, meta-analyses, and the interface between physical health and mental health.

He has authored or co-authored over 800 journal articles that have been cited more than 60.000 times and received over 40 research awards for his work. In November 2022, his H-index was 128 in Google Scholar and 97 in Web of Science.

Since 2014, the beginning of this metric, he has been listed every year by Clarivate/Web of Science as one of the “most influential scientific minds” and “top 1% cited scientists in the area of psychiatry”

read more +

Stephen M. Stahl, MD, PhD, DSc (Hon.)


Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA 

Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA 

Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK  

Editor-in-Chief, CNS Spectrums

Director of Psychopharmacology Services, California Department of State Hospitals, Sacramento, CA 


Dr. Stephen M. Stahl received his undergraduate and medical degrees from Northwestern University in Chicago, as a member of the Honors Program in Medical Education, and his Ph.D. degree in pharmacology and physiology from the University of Chicago. Dr. Stahl has trained in three specialties:  internal medicine at the University of Chicago; neurology at the University of California in San Francisco; and psychiatry at Stanford University.  He is board certified in psychiatry. 

Dr. Stahl has held faculty positions at Stanford University, the University of California at Los Angeles (UCLA), the Institute of Psychiatry London, the Institute of Neurology London, and, currently, as professor at the University of California at San Diego (UCSD) and as an Honorary Visiting Senior Fellow in the Department of Psychiatry at the University of Cambridge in the UK. He also directs psychopharmacology services and academic programs for the eight-facility, 6500 patient California Department of State Hospital System, where he also heads their assessment and treatment efforts to reduce violence.  Dr. Stahl was formerly Executive Director of Clinical Neurosciences at the Merck Neuroscience Research Center in the UK for several years. Dr. Stahl’s major interests are dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology, with a special emphasis on multimedia, the internet and teaching how to teach.

Dr. Stahl currently serves as editor-in-chief of CNS Spectrums. He is also past associate editor of Acta Psychiatrica Scandinavica, former clinical field editor for the International Journal of Neuropsychopharmacology and is currently on numerous editorial boards of other leading journals including the ACNP’s journal Neuropsychopharmacology. He has conducted numerous research projects during his career awarded by the National Institute of Mental Health (NIMH), by the Department of Veteran Affairs (VA) and by the pharmaceutical industry. Author of over 500 articles and chapters, and more than 1600 scientific presentations and abstracts, Dr. Stahl is an internationally renowned clinician, researcher, and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has written 35 books and edited 12 others, including the best-selling and award-winning textbook, Stahl’s Essential Psychopharmacology, now in its fourth edition, the best-selling and award-winning clinical manual, Essential Psychopharmacology Prescriber's Guide, now in its sixth edition.

Lectures, courses, and preceptorships based upon his textbooks have taken him to dozens of countries on 6 continents to speak to tens of thousands of physicians, mental health professionals and students at all levels.  His lectures and scientific presentations have been distributed as more than a million CD-ROMs, internet educational programs, videotapes, audiotapes, and programmed home study texts for continuing medical education to hundreds of thousands of professionals in many different languages.  His courses and award-winning multimedia teaching materials are used by psychopharmacology teachers and students throughout the world.

Dr. Stahl serves as a fellow of the ACNP (American College of Neuro-psychopharmacology), of the British Association of Psychopharmacology (BAP) and of the CINP, where he was formerly vice president and is a Distinguished Life Fellow of the American Psychiatric Association (APA). He also has served on numerous medical and scientific advisory boards for the pharmaceutical industry, for the biotechnology and medical information industry, and for various nonprofit and public service organizations, including appointment by the State of California and past Chair of the Medi-Cal Oversight Board for Medicines (Drug Utilization Review Board).

His educational research programs are monitoring changes in diagnosing and prescribing behaviors as outcomes from various educational interventions for programs organized by the Neuroscience Education Institute, which he chairs.  He also has an active clinical practice specializing in psychopharmacologic treatment of resistant cases.

He has been awarded the International College of Neuropsychopharmacology (CINP) Lundbeck Foundation Award in Education for his contributions to postgraduate education in psychiatry and neurology.  His books have won the British Medical Association’s Book of the Year Award and Arbor Scientia has been awarded the business of the year award from the local chamber of commerce.  Dr. Stahl is also the winner of the A.E. Bennett Award of the Society of Biological Psychiatry, the APA/San Diego Psychiatric Society Education Award, the UCSD department of psychiatry residency teaching award, and has been cited as both one of “America’s Top Psychiatrists” and one of the “Best Doctors in America.”  He was honored with the Distinguished Psychiatrist Award of the APA and gave the Distinguished Psychiatrist Lecture for 2013.  Recently, his alma mater Northwestern University honored him by naming their annual award for the best medical student going into psychiatry the Stephen Stahl award.  Dr. Stahl was named the 2016 David A Mrazek Memorial Award Winner by the American Psychiatric Association and delivered the Mrazek Lecture at the annual meeting of the APA.

read more +